HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Pharming (NASDAQ: PHAR) and maintained a price target of $37 for the stock. This endorsement reflects confidence in the company's performance and potential in the market.